Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Ehave, Inc. (OTC:EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treating brain health. They do so by leveraging clinical data in order to achieve the best results possible.
EHave，Inc.。(場外交易代碼：EHVVF)是一家領先的醫療服務和技術公司，專注於通過設計新的化合物和新的治療方案來治療大腦健康，將迷幻藥進展為治療藥物。他們通過利用臨牀數據來實現這一點，以獲得儘可能好的結果。
Entheon Biomedical Corp. (OTCQB:ENTBF) is a wholly-owned subsidiary of HaluGen Life Sciences Inc., a company that has developed a DNA testing and personalized psychedelic pre-screening platform that provides genetic, personal and familial insights to better inform the psychedelic experience, improving patient care while reducing side effects and risk. Therefore, HaluGen's genetic-based platform helps evaluate an individual's overall sensitivity and risk profile when using hallucinogenic drugs with test results within days.
Entheon Biomedical公司。(OTCQB：ENTBF)是一家全資子公司HaluGen生命科學公司.，一家開發了DNA測試和個性化迷幻預篩查平臺的公司，該平臺提供遺傳、個人和家庭洞察，以更好地告知迷幻體驗，改善患者護理，同時減少副作用和風險。因此，HaluGen的基於基因的平臺有助於在幾天內使用具有測試結果的致幻藥物時評估個人的整體敏感性和風險概況。
Both companies have combined their efforts and the result is a new expanded psychedelics genetic testing panel for Ehave's subsidiary psychedelics company, KetaDASH. The device will analyze a series of relevant DNA biomarkers and use pre-screening mental health surveys to understand a given individual's risk and potential of adverse reactions with the use of ketamine.
兩家公司已經聯合起來努力結果是eHave的子公司迷幻藥公司的一個新的擴展迷幻藥基因測試小組，凱塔·達什。該設備將分析一系列相關的DNA生物標記物，並使用預先篩查的精神健康調查，以瞭解特定個人使用氯胺酮的不良反應的風險和可能性。
The new device will provide results that will be, then, absolutely personal.
新設備將提供結果那麼，這將是絕對的個人隱私。
On the other hand, genetics can play a key role in determining how an individual may respond to psychedelic-assisted psychotherapy. Specifically, the gene mutation CYP2B6 can influence the metabolism of ketamine for the 10-20% of people that carry a specific variant. Similarly, the HTR2A gene mutation, present in nearly 20% of the population, can impact how a person responds to serotonin, which is the primary mechanism of action for serotonergic psychedelics such as psilocybin, LSD and DMT.
另一方面，遺傳學可以在決定個體對迷幻輔助心理治療的反應方面發揮關鍵作用。具體地説，基因突變CYP2B6會影響10%-20%攜帶特定變異的人的氯胺酮代謝。同樣，HTR2A基因突變存在於近20%的人口中，可以影響人對5-羥色胺的反應，5-羥色胺是裸蓋菇素、LSD和DMT等5-羥色胺能迷幻劑的主要作用機制。
It is expected that precision medicine will provide KetaDASH with the ability to tailor the treatment based on an individual or sub-groups variability in genes and lifestyle choice.
預計精確醫學將為KetaDASH提供根據個人或亞組基因和生活方式選擇的變異性進行量身定製治療的能力。
As Ehave CEO Ben Kaplan put it, "The benefit of the psychedelic profile is that it will enable the individuals and healthcare professionals at KetaDASH to personalize psychedelic therapy by providing an individual's metabolic status for ketamine with their CYP2B6 genotype."
作為eHave首席執行官本·卡普蘭換言之，“迷幻檔案的好處是，它將使KetaDASH的個人和醫療保健專業人員能夠通過提供帶有他們的CYP2B6基因的氯胺酮的代謝狀態來個性化迷幻療法。”
This is a point of view shared by Entheon CEO Timothy Ko. "We believe that personalization will become an increasingly important feature of the psychedelic therapeutics landscape."
這一觀點得到了Entheon首席執行官蒂莫西·科。我們相信，個性化將成為迷幻療法的一個日益重要的特徵。“
Photo Courtesy of Pixabay
圖片由Pixabay提供
譯文內容由第三人軟體翻譯。